Skip to main content
. 2015 Jun 5;5:11030. doi: 10.1038/srep11030

Figure 1. Vasculotide (VT) protects and rescues mice from severe influenza virus infection.

Figure 1

(a) Basic experimental protocol used to test VT in mice infected with influenza virus. Arrows indicate the time after infection (hours) at which daily administration of VT was begun. C57BL/6J mice were infected with mouse-adapted influenza, strain X31 and received placebo or 500 ng VT per day starting at the indicated times. (b) Survival was monitored daily; numbers in parentheses indicate the number of mice per group. ***p < 0.001 vs. flu-alone mice. (c) Arterial oxygen saturation on day 5 after infection, ***p < 0.001. (d) Lung edema was measured by wet-to-dry ratio in mice sacrificed 5 days after infection. (e) Left ventricular ejection fraction on day 5 after infection was measured by echocardiography. (f) C57BL/6J mice were infected with mouse-adapted influenza, strain PR8 and received placebo or 500 ng VT daily starting at 48 hours after infection, *p < 0.05.